Cumberland Pharmaceuticals Inc (CPIX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $88.16M
Last updated: Nov 17, 2026 at 11:03 AM ET
Cumberland Pharmaceuticals Inc (CPIX) Financials: Revenue, Profit and Cash Flow
Cumberland Pharmaceuticals reported revenue of $44.52M for the fiscal year ended Dec 31, 2025, up 17.6% from the year before. That year, net income was -$2.86M with a net margin of -6.4%, operating cash flow was $4.93M and free cash flow was $4.83M. The quarter ended Sep 30, 2026 had revenue of $2.16M and net income of $77.78M.
Revenue and Margins
The operating margin was -6.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $33.03M, a compound annual rate of 3.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $44.52M | +17.6% | 85.0% | -6.3% | -6.4% |
| Dec 2024 | $37.87M | -4.3% | 82.6% | -17.0% | -17.0% |
| Dec 2023 | $39.55M | -5.9% | 84.7% | -24.2% | -16.0% |
| Dec 2022 | $42.01M | +16.7% | 78.3% | -13.6% | -13.4% |
| Dec 2021 | $35.99M | -3.9% | 75.5% | -21.3% | -10.0% |
| Dec 2020 | $37.44M | +8.9% | 76.9% | -17.0% | -9.1% |
| Dec 2019 | $34.39M | +17.2% | 78.4% | -27.0% | -10.3% |
| Dec 2018 | $29.34M | -28.7% | 79.5% | -38.1% | -24.0% |
| Dec 2017 | $41.15M | +24.6% | 82.1% | -9.9% | -19.6% |
| Dec 2016 | $33.03M | N/A | 82.0% | -4.3% | -3.0% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.52M | $37.87M | $39.55M | $42.01M | $35.99M | $37.44M | $34.39M | $29.34M | $41.15M | $33.03M |
| Cost of revenue | $6.67M | $6.59M | $6.07M | $9.12M | $8.81M | $8.65M | $7.42M | $6.02M | $7.37M | $5.96M |
| Gross profit | $37.85M | $31.28M | $33.49M | $32.89M | $27.17M | $28.79M | $26.97M | $23.33M | $33.78M | $27.07M |
| Research and development | $5.57M | $4.82M | $5.83M | $6.69M | $5.68M | $5.77M | $6.87M | $7.58M | $4.28M | $3.19M |
| Operating income | -$2.79M | -$6.43M | -$9.55M | -$5.70M | -$7.68M | -$6.38M | -$9.29M | -$11.17M | -$4.08M | -$1.43M |
| Net income | -$2.86M | -$6.44M | -$6.33M | -$5.65M | -$3.60M | -$3.42M | -$3.55M | -$7.04M | -$8.05M | -$1.00M |
| EBITDA | $2.52M | -$123.71K | -$118.01K | $245.75K | -$849.86K | -$1.59M | -$4.84M | -$8.09M | -$1.36M | $1.05M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.16M | $166.46K | $9.13M | $13.68M | $171.82K | $380.80K | $11.71M | $10.44M | $9.09M | $9.85M | $8.50M | $9.35M |
| Gross profit | $2.16M | $166.46K | $7.20M | $11.44M | $171.82K | $380.80K | $10.29M | $8.46M | $7.76M | $8.14M | $6.92M | $7.82M |
| Operating income | -$1.94M | -$3.16M | -$3.13M | -$1.37M | -$2.86M | -$3.12M | $1.29M | -$1.84M | -$1.69M | -$1.03M | -$1.87M | -$6.18M |
| Net income | $77.78M | -$4.27M | -$3.29M | -$1.43M | -$1.95M | -$735.21K | $1.25M | -$1.90M | -$1.54M | -$1.10M | -$1.90M | -$6.30M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $5.71M by $5.74M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $76.82M | $75.58M | $81.78M | $92.93M | $84.46M | $96.46M | $104.55M | $112.69M | $93.23M | $93.40M |
| Current assets | $37.06M | $36.45M | $35.71M | $45.87M | $45.69M | $49.97M | $50.16M | $59.12M | $68.68M | $65.55M |
| Cash and equivalents | $11.44M | $17.96M | $18.32M | $19.76M | $27.04M | $24.75M | $28.21M | $27.94M | $45.41M | $34.51M |
| Total liabilities | $52.28M | $53.04M | $52.52M | $56.95M | $41.86M | $49.59M | $53.46M | $57.12M | $29.31M | $20.28M |
| Short-term debt | $467.77K | $5.10M | $0 | $172.91K | $969.68K | $3.20M | $920.43K | N/A | $9.80M | $4.10M |
| Long-term debt | $5.24M | $10.18M | $12.78M | $16.20M | $15.00M | $15.00M | $18.50M | $20.00M | $9.80M | $4.10M |
| Shareholder equity | $24.88M | $22.85M | $29.60M | $36.27M | $42.81M | $46.99M | $51.12M | $55.84M | $64.12M | $73.25M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $113.78M | $62.88M | $71.00M | $76.82M | $65.90M | $67.91M | $69.94M | $75.58M | $76.75M | $78.52M | $81.51M | $81.78M |
| Total liabilities | $41.60M | $45.77M | $49.69M | $52.28M | $40.10M | $40.23M | $41.60M | $53.04M | $52.28M | $52.49M | $54.32M | $52.52M |
| Cash and equivalents | $80.58M | $3.86M | $11.01M | $11.44M | $15.20M | $16.09M | $15.11M | $17.96M | $17.46M | $17.34M | $18.55M | $18.32M |
| Shareholder equity | $72.51M | $17.44M | $21.64M | $24.88M | $26.12M | $27.99M | $28.66M | $22.85M | $24.78M | $26.35M | $27.49M | $29.60M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.0% of operating cash flow. Share repurchases came to 5.5% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.93M | -$612.19K | $6.09M | $8.45M | $6.34M | $5.42M | $3.06M | $3.11M | -$557.71K | $569.48K |
| Capital expenditures | $97.90K | $66.46K | $281.27K | $102.15K | $103.53K | $140.82K | $246.20K | $455.57K | $275.96K | $130.87K |
| Free cash flow | $4.83M | -$678.65K | $5.81M | $8.35M | $6.24M | $5.27M | $2.81M | $2.66M | -$833.67K | $438.61K |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $135.41K | N/A | $56.00M | $0 | $0 |
| Share repurchases | $263.48K | $579.05K | $740.53K | $1.05M | $1.39M | $1.99M | $3.49M | $3.26M | $3.75M | $2.52M |
| Investing cash flow | -$4.71M | $57.84K | -$105.69K | -$13.67M | -$501.89K | -$1.76M | $2.30M | -$27.72M | $9.51M | -$3.12M |
| Financing cash flow | -$6.75M | $196.90K | -$7.42M | -$2.06M | -$3.55M | -$7.12M | -$5.08M | $7.14M | $1.95M | -$1.15M |
Quarterly
| Line item | Sep 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.50M | $387.02K | $3.02K | $187.18K | $843.80K | $3.90M | $1.90M | $475.50K | -$855.66K | -$2.14M | $1.04M | $1.24M |
| Capital expenditures | $9.81K | $0 | $1 | $23.79K | $26.49K | $47.63K | $2.28K | $15.38K | $7.18K | $41.62K | $48.67K | $53.14K |
| Free cash flow | -$1.51M | $387.02K | $3.02K | $163.39K | $817.32K | $3.85M | $1.90M | $460.12K | -$862.84K | -$2.18M | $991.45K | $1.18M |
Frequently Asked Questions About CPIX
What is Cumberland Pharmaceuticals' annual revenue?
Cumberland Pharmaceuticals reported revenue of $44.52M for the fiscal year ended Dec 31, 2025.
How fast is Cumberland Pharmaceuticals' revenue growing?
Revenue was up 17.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.0%.
Is Cumberland Pharmaceuticals profitable?
No. Cumberland Pharmaceuticals reported net income of -$2.86M for the fiscal year ended Dec 31, 2025, with a net margin of -6.4%.
How much free cash flow does CPIX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $4.93M minus capital expenditures of $97.90K produced free cash flow of $4.83M.
How much debt does Cumberland Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $5.24M, short-term debt of $467.77K and cash and equivalents of $11.44M.
CPIX pages: Overview, Earnings, Financials, Valuation, Competitors